Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Novel Monoclonal Antibody Blocks Breast Cancer Metastasis in Mouse Model

By BiotechDaily International staff writers
Posted on 01 Jul 2013
Print article
Image: Metastasized human breast cancer cells (magnified 400 times, stained brown) in lymph nodes (Photo courtesy of the [US] National Cancer Institute).
Image: Metastasized human breast cancer cells (magnified 400 times, stained brown) in lymph nodes (Photo courtesy of the [US] National Cancer Institute).
A monoclonal antibody specific for the protein ROR1 (Receptor-tyrosine-kinase-like Orphan Receptor 1) was found to inhibit cell migration and invasion in cancer cell cultures and block tumor metastasis in a mouse breast cancel model.

Investigators at the University of California, San Diego (USA) had shown previously that ROR1, which is expressed during embryonic development and by various cancers, was not active in normal postpartum tissues. In the current study, which was published in the June 15, 2013, issue of the journal Cancer Research, the investigators linked expression of ROR1 to the process of epithelial-mesenchymal transition (EMT). EMT is a process by which epithelial cells lose their cell polarity and cell-cell adhesion, and gain migratory and invasive properties to become mesenchymal cells. EMT is essential for numerous developmental processes including mesoderm formation and neural tube formation. EMT has also been shown to occur in wound healing, in organ fibrosis, and in the initiation of metastasis for cancer progression.

The investigators found that breast adenocarcinomas expressing high levels of ROR1 were more likely to have gene expression signatures associated with EMT and had higher rates of relapse and metastasis than breast adenocarcinomas expressing low levels of ROR1. Suppressing expression of ROR1 in metastasis-prone breast cancer cell lines attenuated expression of proteins associated with EMT and impaired their capacity for migration and invasion in vitro and for metastasis in immunodeficient mice.

Treatment of a mouse breast-cancer model with a monoclonal antibody specific for ROR1 induced down modulation of EMT-promoting proteins and inhibited cancer cell migration and invasion in vitro and tumor metastasis in vivo. The investigators concluded that this finding indicated that antibodies targeting ROR1 could inhibit cancer progression and metastasis.

“We might think of ROR1 as an oncogene,” said first author Dr. Bing Cui, a postdoctoral researcher at the University of California, San Diego. “This means ROR1 has some tumor initiation functions. However, ROR1 also appears to allow transformed cells to invade other tissues and to promote tumor expansion in both the primary tumor site and in distant organs.”

Related Links:
University of California, San Diego


Print article

Channels

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A 3D nanofiber net formed by the supergelators to trap oil molecules (Photo courtesy of IBN at A*STAR / Institute of Bioengineering and Nanotechnology).

Effective Cleanup with Smart Material That Forms Oil-Trapping Net

Researchers have developed supergelators – an organic oil-scavenging material that rapidly forms a 3D net to trap oil molecules, gelatinizing into solidified masses that can be more easily removed from... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.